Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | CBS | P35520 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1610704 | 1.00 | HRH3 (0.39) | HRH3CBSMAPTSMN1; SMN2HTR1D | |
| SCHEMBL1610329 | 0.98 | HRH3 (0.40) | HRH3HTR1DCYP11B1CYP11B2 | |
| SCHEMBL1609708 | 0.92 | HRH3 (0.41) | HRH3HTR1DCYP11B1CYP11B2 | |
| SCHEMBL1610963 | 0.85 | HRH3 (0.42) | HRH3HTR1DCYP11B1CYP11B2 | |
| SCHEMBL1611097 | 0.82 | KMT2A (0.32) | — | |
| SCHEMBL1611395 | 0.82 | KMT2A (0.32) | — | |
| SCHEMBL1611645 | 0.81 | — | — | |
| SCHEMBL1610890 | 0.81 | — | — | |
| SCHEMBL1609702 | 0.80 | — | — | |
| SCHEMBL1610903 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110087034-A1 | Organic Semiconductor Material | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2011-04-14 | — | — | US | disclosed |
| EP-2248818-A1 | ORGANIC SEMICONDUCTOR MATERIAL | Sumitomo Chemical Company, Limited (JP) | 2010-11-10 | — | — | EP | disclosed |
| US-3987087-A | ANTI-ULCER, NASAL PATENCY, WOUND HEALING, LABOR INDUCEMENT | THE UPJOHN COMPANY (US) | 1976-10-19 | — | — | US | disclosed |
| US-3983158-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1976-09-28 | — | — | US | disclosed |
| US-3983157-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1976-09-28 | — | — | US | disclosed |
| US-3980694-A | ANTIULCER, ANTIAGGLOMERANTS, INCREASE OF NASAL PATENCY, LABOR INDUCEMENT, WOUND HEALINGPROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1976-09-14 | — | — | US | disclosed |
| US-3931289-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110087034-A1 | Organic Semiconductor Material | OR10J3, TST, OR51E2 | HRH3 119/4885CBS 85/4885MAPT 3838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.